Study of Tamoxifen and Raloxifene concludes at North Star Lodge With Trial Participants Reunion

STAR  (Study of Tamoxifen and Raloxifene)

Concludes at North Star Lodge With Trial Participants Reunion


After thirteen years, the study of Tamoxifen and Raloxifene has concluded in Yakima County and throughout the nation.  The primary goal of the study was to determine if Raloxifene is either more or less effective than Tamoxifen in reducing the incidence of invasive breast cancer among postmenopausal women.


This national study funded by the National Cancer Institute selected 19,747 women nationwide to participate.  North Star Lodge clinical trials program was selected to lead one of the many studies throughout the nation.  They screened 521 women throughout Central Washington which resulted in 61 eligible participants who entered the 5 year study.  (Yakima 39, Upper Valley 9, Lower Valley 8, Tri Cities 2, Goldendale 1, Walla Walla 1, Wenatchee 1).  There were 53 participants who ultimately completed the study which officially ended May 31, 2012.


The results after 81 months, (5 years of medication and 21 months of follow-up) showed that Raloxifene reduces the risk of breast cancer by about 38% compared to Tamoxifen reducing breast cancer by about 50%.


North Star Lodge Clinical Trials program offers 35-40 active trials at any given time and are commonly chosen to lead rare trials and those that are very close to FDA approval.


The local study members met for a farewell gathering last Wednesday, August 15, 2012, 2pm – 3:30 pm at North Star Lodge.  Take a look at this news story from KIMA-TV.